Penn Abramson Cancer Center Researcher Presents
at AAAS Annual Meeting On the
Implications of Genetic Research on Cancer Prevention
Presentations: Sunday, February 20th,
8:30 – 11:30 a.m.
Press Briefings: 2 p.m. in the Taft Room
Marriott Wardman Park Hotel, Mezzanine Level
(Philadelphia, PA) Timothy R. Rebbeck, Ph.D., Director
of the Cancer Epidemiology and Risk Reduction Program of the Abramson
Cancer Center of the University of Pennsylvania, will be presenting
“Genetic Screening and Cancer Risk Reduction: BRCA1 and BRCA2 ”
at the 2005 AAAS Annual Meeting in Washington, DC, being held this Thursday
through Monday, February 17-20th.
As part of the Sunday symposium “Cancer Screening and Its Impact
on Cancer Mortality,” Rebbeck will discuss the implications of genetic
research in cancer prevention. “We have acquired vast amounts of
information about the human genome, but what does it mean?” asks
Rebbeck. “How can we apply this information into better understanding
a woman’s risk of breast cancer or ovarian cancer? And perhaps most
importantly, how can we use knowledge of the human genome to improve cancer
treatment and prevention?”
According to Rebbeck, the impact of the human genome initiatives will
only be realized if we can use this information to identify cancer susceptibility
genes that are truly causal and minimize the potential for spurious relationships.
This requires the proper development and application of approaches that
address the complex genetic and environmental causes of human cancer,
and the utilization of appropriate methods to translate this information
into cancer prevention and treatment options.
Rebbeck, a Professor of Biostatistics and Epidemiology at the University
of Pennsylvania School of Medicine, will be available to discuss
the promise of the human genome for improving human health and disease
during the 2 p.m. news briefing on Sunday, February 20th.
The Abramson Cancer Center of the University of Pennsylvania
was established in 1973 as a center of excellence in cancer research,
patient care, education and outreach. Today, the Abramson Cancer Center
ranks as one of the nation’s best in cancer care, according to U.S.
News & World Report, and is one of the top five in National Cancer
Institute (NCI) funding. It is one of only 39 NCI-designated comprehensive
cancer centers in the United States. Home to one of the largest clinical
and research programs in the worlds, the Abramson Cancer Center of the
University of Pennsylvania Has 275 active cancer researchers and 250 Penn
Physicians involved in cancer prevention, diagnosis and treatment.
PENN Medicine is a $2.7 billion enterprise dedicated
to the related missions of medical education, biomedical research, and
high-quality patient care. PENN Medicine consists of the University of
Pennsylvania School of Medicine (founded in 1765 as the nation’s
first medical school) and the University of Pennsylvania Health System
(created in 1993 as the nation’s first integrated academic health
Penn’s School of Medicine is ranked #3 in the nation for receipt
of NIH research funds; and ranked #4 in the nation in U.S. News &
World Report’s most recent ranking of top research-oriented medical
schools. Supporting 1,400 fulltime faculty and 700 students, the School
of Medicine is recognized worldwide for its superior education and training
of the next generation of physician-scientists and leaders of academic
Penn Health System is comprised of: its flagship hospital, the Hospital
of the University of Pennsylvania, consistently rated one of the nation’s
“Honor Roll” hospitals by U.S. News & World Report; Pennsylvania
Hospital, the nation's first hospital; Presbyterian Medical Center; a
faculty practice plan; a primary-care provider network; two multispecialty
satellite facilities; and home health care and hospice.